U.S. Animal model Market Outlook—2022-2032
[155 Pages] The demand in the U.S. animal model is set to increase at a 4.1% CAGR from 2022 to 2032, with the market valuation reaching around US$ 947.3 Mn in 2022. According to a recent study by Future Market Insights, mice held a substantial share of over 62.0% in 2021 within the U.S. market.
U.S. Animal Model Market Value (2021)
US$ 921.9 Mn
U.S. Animal Model Market Estimated Value (2022)
US$ 947.3 Mn
U.S. Animal Model Market Projected (Value) 2032
US$ 1.4 Bn
U.S. Animal Model Market Value-based CAGR (2022-2032)
Animal model plays a valuable role in clinical research for the development of new drugs and treatments. Almost 90% of the processes for the development of drugs are depended on the testing of animal models.
Noticeable similarities, such as anatomical and physiological similarities, in humans and animals make animal models essential for biological research and drug development. Furthermore, growing need for novel drugs and customized medicines will boost the demand for animal models for clinical studies.
Rising trend of genetically modified animal models, such as genetically engineered mice (transgenic, knockout, knock-in, humanized) for the study of genetic diseases, multifactorial and polygenic (complex) disorders, neurodegenerative diseases, inflammatory diseases, and is boosting the growth in the market.
In 2021, the U.S. animal model held nearly 60% of the global animal model market worth US$ 1.5 Bn.
Sales Analysis of U.S. Animal Model from 2017 to 2021 Vs Market Outlook for 2022 to 2032
Demand in the U.S. animal model market increased at a 3% CAGR between 2017 to 2021. As per the report, sales are projected to grow at a 4.1% CAGR over the forecast period, on the back of surging demand for animal model for regenerative medicine and tissue engineering.
The presence and dominance of CROs in the country, which involve animal models in their research, and increasing focus on personalized medications are key factors expected to drive demand in the U.S.
Due to the advent of COVID-19, people are giving priority to being fully vaccinated. With increasing vaccinations rates and rising awareness, demand for clinical research and studies is increasing. This has a direct impact on the demand for animal model as it is used in the development of various vaccines.
Further, ongoing research and development in the healthcare sector for the development of regenerative medicine and tissue engineering are propelling demand for animal model. Growing usage of animal model-based preclinical interpretation of new therapeutics and drug discovery & development will fuel sales in the market.
What are the Key Opportunities for U.S. Animal Model Manufacturers?
Animal models are effective tools for conducting preclinical studies to learn more about human biology. The need to understand how drugs work in humans, as well as growing interest in investigating human-specific diseases, therapies, and immune responses, are driving the development and usage of animal models.
Increasing prevalence of diseases is compelling the government to focus on preventive measures. This is driving investments for performing clinical trials on animal models. For instance, in March 2020, the FDA spent around US$ 250,000 on the testing of coronavirus on animal models including monkeys, mice, ferrets, and others.
Hefty investments and policy reforms by the government have stimulated funding schemes with regard to animal model research, which is creating opportunities for growth in the market.
In addition to this, different species of animal models have different anatomy, physiology, lifespan, and disease characteristics. Therefore, some experiments on animals do not provide conclusive information on patient outcomes. For accurate clinical research in the discovery of drugs, there is still a need for perfect genetically modified animal models.
Animal model providers are benefitting from the next-generation sequencing technology and genome engineering tools to provide custom and rare disease models, with a focus on supporting personalized therapy drug trials.
For instance, Charles River Laboratories provides hACE2-NCG mouse models specifically designed for COVID-19 research. Such developments are expected to bode well for the market over the forecast period.
What are the Factors Restraining Demand in the U.S. Animal Model Market?
Delay in drug approvals and reduced possibilities of medication for human use can hamper the growth of the animal model market. Drugs that survive clinical trials and get approved are sometimes recalled because of toxicity identified in them after a few months or years.
Some animal models have limited ability to mimic proper complex processes of human physiology, progression, and carcinogenesis. Due to this, safety and efficacy identified in animal studies sometimes cannot be considered for humans. In many cases, certain mouse models’ physiological changes occur in the spectrum that do not occur in the human disease.
Additionally, some animal model tests take months or years to conduct and analyse. For example, approximately 4-5 years are taken for rodent cancer studies, which involves thousands and sometimes millions of dollars.
Due to the high costs of animal model clinical trials, government regulatory agencies and scientific organizations are finding alternative methods to replace animal testing and provide improvements in the safety of new medications for human use. This can hamper the growth of the animal model market.
Which Species is Driving Sales?
“Demand in the Mice Model Segment Will Gain Momentum”
In terms of species, total sales in the mice model segment are expected to hold a market share value of around 62.6% in 2022, with sales growing at a 5.1% over the forecast period.
Mice models are one of the most important tools for performing preclinical research to acquire insights into human biology as they are genetically similar to humans. These models are created by engrafting human cells or tissues into mice, resulting in the expression of human proteins.
Mice are increasingly being employed as models in biomedical research for HIV/AIDS, cancer, regenerative medicine, hepatitis, and infectious disease research. They are being developed and used in response to a growing need to determine the true effects of medications on humans.
Besides this, growing focus on researching human-specific infections, therapies, and immunological responses will continue pushing sales in this segment in the forthcoming years.
Which is the Leading Therapeutics Segment in the Animal Model Market?
“Sales of Animal Models for Oncology Research to Remain High”
Based on therapeutics, the oncology segment held nearly 32.6% of the total market share in 2021, and the trend is expected to continue over the forecast period. Animal models are widely used in oncology to study the biochemical and physiological processes of the occurrence and development of cancer. They help in determining the most appropriate treatment approach for specific cancers.
Presently, there is a huge global burden of chronic diseases, including cancer. In vitro as well as in vivo approaches are being developed to fight against the rising prevalence of cancer. One of the most significant advancements is the development of humanized mouse and rodent models, as they offer high prescient power for the viability of standard and novel anti-cancer therapeutics.
Factors such as the importance of personalized medicine, monoclonal antibodies and the potential to treat diseases easily on a personal level are expected to fuel sales in this segment.
Which Application Holds a Dominant Share in the U.S. Animal Model Market?
“Adoption of Animal Models in Novel Drug Discovery will Continue Increasing”
By application, total sales of animal model in the drug discovery/development segment accounted for 65.4% of the total market share in 2021. Drug discovery/development is invariably a lengthy and costly process. It begins with the identification and validation of a potential molecular/cellular therapeutic target, and moves through a series of preclinical and clinical trials, culminating in a series of regulatory approvals. The usage of experimental animal models helps researchers better understand the genesis, pathophysiology, and overall character of human diseases.
Animal models for drug discovery and development have played a crucial role in the characterization of disease pathophysiology and associated mechanisms of injury and target identification.
They are also used for the evaluation of novel therapeutic agents for toxicity/safety, pharmacodynamics, pharmacokinetics, and efficacy for the development of safe and effective therapies and cures for diseases and/or symptoms connected with them.
Which End User Benefits the Most by the Employment of Animal Model?
“Applications of Animal Model in Academic and Research Institutes Will Gain Traction”
Based on end user, demand in the academic & research institutes segment more than 36.6% of the total market share in 2021. Growth can be attributed to increasing establishments of academic & research institutes in the country for the development of drugs and vaccines for various chronic diseases. Researchers utilize animal models to examine and assemble evidence-based findings to address different health-related problems.
Furthermore, the availability of highly qualified and skilled scientists at academic & research institutes will also contribute to the growth in this segment.
The U.S. animal model market is fragmented with the presence of established as well emerging market players. These players are actively investing in acquisitions, collaborations, and product launches as key strategies. For instance:
- In January 2022, Taconic Biosciences launched huNOG-EXL EA (Early Access) humanized immune system mouse. This unique mouse model supports human myeloid and lymphoid cells, which makes this mice model useful for immunological and oncological research.
- In April 2021, Ingenious Targeting Laboratory and SMOC collaborated to produce and distribute catalogue mouse models for Ingenious Targeting Laboratory to distribute SMOC’s validated off-the-shelf mouse models in North America and Europe.
- In June 2021, the Dana-Farber Cancer Institute and Harbour BioMed collaborated to work on novel biotherapies for cancer treatment. Both organizations worked together on the development of CAR-T cell products and biospecific antibodies.
Report Scope as per U.S. Animal model Industry Analysis
Historical Data Available for
US$ Mn for Value
Key Countries Covered
Key Market Segments Covered
Species, Therapeutics, Applications, and End User
Key Companies Profiled
Available upon Request
Frequently Asked Questions
The U.S. animal model market is worth US$ 921.9 Mn in 2021 and is set to expand 1.5X over the next ten years.
The animal model market is expected to reach US$ 1.4 Bn by the end of 2032, with sales revenue expected to register a 4.1% CAGR.
An increase in the use of personalized medicine, and rapid developments in regenerative medicine and tissue engineering are some of the key trends expected to drive sales in the market.
Rising usage of animal models in pre-clinical development in several research laboratories and biopharmaceutical industries, along with rapid adoption of animal models for vaccine development and testing are expected to boost the market.
Funding opportunities for developing new methods in healthcare management and the use of advanced tools and technology are some of the key opportunities in the animal model market.
Charles River Laboratories, The Jackson Laboratory, Taconic Biosciences, Inc., Genoway, Envigo (Inotiv, Inc.), Marshall BioResources, Janvier Labs, Applied stem cells, Biocytogen, Transposagen Biopharmaceuticals, Inc. (Hera Bio Labs), Cyagen, Ingenious targeting labs, Crown Bioscience Inc. (JSR Corporation), Harbour Biomed, Sinclair Bio Resources, Alpha Genesis Inc., Creative Animodel, and DaVinci Biomedical Research Products, Inc. are the key players in the U.S. animal model market.
1. Executive Summary
1.1. U.S. Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion & Exclusion
3. Key Market Trends
3.1.1. Key Trends Impacting The Market
3.1.2. Innovation / Development Trends
4. Market Background
4.1. Macro-Economic Factors
4.1.1. U.S. GDP Growth Outlook
4.1.2. U.S. Healthcare Expenditure Outlook
4.1.3. U.S. Pharmaceutical Industry Outlook
4.2. Forecast Factors - Relevance & Impact
4.2.1. Increasing Intent of Academic & Research Institutions
4.2.2. Increasing Number Of Vaccine Testing and Development
4.2.3. Disease Prevalence and Growth
4.2.4. Rising Focus on Technological Advancements in Biotechnology
4.2.5. Increased Funding and Support from Government
4.2.6. Adoption Rate
4.2.7. Increasing Number of Clinical Trials
4.2.8. Increasing Preference for Customized Animal Models
4.3. Market Dynamics
4.3.3. Opportunity Analysis
5. Key Success Factors
5.1. Application Vs Animal Model Intensity Mapping
5.2. Key Strategies by Manufacturers
5.3. PESTLE Analysis
5.4. Porters Analysis
5.5. Key Regulations
5.6. Supply Chain Analysis
5.7. Cost Structure
5.8. Type of Animal Model and Analysis thereof
5.9. Animal Model in Disease Research
5.10. Animal Model for Clinical Research
5.11. List of animal model suppliers in the U.S.
5.11.1. Small Animals
5.11.2. Large Animals
5.12. Animal model outlook in Boston
5.12.1. Market Size by Animal in Boston, 2021
5.12.2. Demand Trends
18.104.22.168. Small Animals
22.214.171.124. Large Animals
5.12.3. Animal Model Lab Layout
6. COVID19 Crisis Analysis
6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Current Economic Projection as compared to 2008 Economic analysis
6.4. COVID19 and Impact Analysis
6.4.1. By Species
6.4.2. By Therapeutic Area
6.4.3. By Application
6.4.4. By End User
6.4.5. By Country
7. U.S. Animal Model Market Demand (US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032
7.1. Historical Market Value (US$ Mn) Analysis, 2017–2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
126.96.36.199. Y-o-Y Growth Trend Analysis
188.8.131.52. Absolute $ Opportunity Analysis
8. U.S. Animal Model Market Analysis 2017-2021 and Forecast 2022-2032, by Species Introduction / Key Findings
8.1. Introduction/Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Species, 2017 – 2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Species, 2022 - 2032
8.3.8. Other Species
8.4. Market Attractiveness Analysis By Species
9. U.S. Animal Model Market Analysis 2017-2021 and Forecast 2022-2032, by Application
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Application, 2017 – 2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2022 – 2032
9.3.1. Drug Discovery/Development
9.3.2. Basic and Applied Research
9.4. Market Attractiveness Analysis By Application
10. U.S. Animal Model Market Analysis 2017-2021 and Forecast 2022-2032, by Therapeutic Area
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Therapeutic Area, 2017 – 2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Therapeutic Area, 2022 - 2032
10.3.1. Metabolic Disease
10.3.2. Cardiovascular Disease
10.3.3. Neurologic Disease
10.4. Market Attractiveness Analysis By Therapeutic Area
11. U.S. Animal Model Market Analysis 2017-2021 and Forecast 2022-2032, by End User
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By End User, 2017 - 2021
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022 - 2032
11.3.1. Academic & Research Institutions
11.3.2. Pharmaceutical Companies
11.3.3. Biotechnology Companies
11.3.4. Contract Research Organizations (CROs)
11.3.5. Other End Users
11.4. Market Attractiveness Analysis By End User
12. Market Structure Analysis
12.1. Market Analysis by Tier of Companies
12.2. Market Concentration
12.3. Market Share Analysis of Top Players
13. Competition Analysis
13.1. Competition Dashboard
13.2. Competition Benchmarking
13.3. Competition Deep Dive
13.3.1. Charles River Laboratories International, Inc.
184.108.40.206. Product Portfolio
220.127.116.11. Strategy Overview
18.104.22.168.1. Marketing Overview
22.214.171.124.2. Product Strategy
126.96.36.199.3. Channel Strategy
13.3.2. The Jackson Laboratory
188.8.131.52. Product Portfolio
184.108.40.206. Strategy Overview
220.127.116.11.1. Marketing Overview
18.104.22.168.2. Product Strategy
22.214.171.124.3. Channel Strategy
13.3.3. Deerland Probiotics & Enzymes Inc.
126.96.36.199. Product Portfolio
188.8.131.52. Strategy Overview
184.108.40.206.1. Marketing Overview
220.127.116.11.2. Product Strategy
18.104.22.168.3. Channel Strategy
13.3.4. Trans Genic Inc.
22.214.171.124. Product Portfolio
126.96.36.199. Strategy Overview
188.8.131.52.1. Marketing Overview
184.108.40.206.2. Product Strategy
220.127.116.11.3. Channel Strategy
13.3.5. Taconic Biosciences, Inc.
18.104.22.168. Product Portfolio
22.214.171.124. Strategy Overview
126.96.36.199.1. Marketing Overview
188.8.131.52.2. Product Strategy
184.108.40.206.3. Channel Strategy
13.3.6. Genoway SA
220.127.116.11. Product Portfolio
18.104.22.168. Strategy Overview
22.214.171.124.1. Marketing Overview
126.96.36.199.2. Product Strategy
188.8.131.52.3. Channel Strategy
13.3.7. Crown Bioscience, Inc.
184.108.40.206. Product Portfolio
220.127.116.11. Strategy Overview
18.104.22.168.1. Marketing Overview
22.214.171.124.2. Product Strategy
126.96.36.199.3. Channel Strategy
13.3.8. Envigo CRS SA
188.8.131.52. Product Portfolio
184.108.40.206. Strategy Overview
220.127.116.11.1. Marketing Overview
18.104.22.168.2. Product Strategy
22.214.171.124.3. Channel Strategy
13.3.9. Transposagen Biopharmaceuticals, Inc.
126.96.36.199. Product Portfolio
188.8.131.52. Strategy Overview
184.108.40.206.1. Marketing Overview
220.127.116.11.2. Product Strategy
18.104.22.168.3. Channel Strategy
14. Assumptions and Acronyms Used
15. Research Methodolog
Figure 01: U.S. Animal Model Market Value (US$ Mn) Forecast, 2022 – 2032
Figure 02: U.S Animal Model Market Value Share, By Species 2022(E)
Figure 03: U.S Animal Model Market Value Share, By Therapeutics 2022(E)
Figure 04: U.S Animal Model Market Value Share, by Application 2022(E)
Figure 05: U.S Animal Model Market Value Share, By End User 2022(E)
Figure 6: U.S. Animal Model Market Size (‘US$ Mn) Analysis, 2017-2021
Figure 7: U.S. Animal Model Market Current and Future Market Value (US$ Mn), 2022-2032 & Y-o-Y Growth Trend Analysis
Figure 8: U.S. Animal Model Market Absolute $ Opportunity, 2022–2032
Figure 9: U.S. Animal Model Market Share Analysis (%) By Species, 2022 & 2032
Figure 10: U.S. Animal Model Market Y-o-Y Growth (%) By Species, 2022-2032
Figure 11: U.S. Animal Model Market Attractiveness Analysis, By Species
Figure 12: U.S. Animal Model Market Share Analysis (%) By Application, 2022 & 2032
Figure 13: U.S. Animal Model Market Y-o-Y Growth (%) By Application, 2022-2032
Figure 14: U.S. Animal Model Market Attractiveness Analysis, By Application
Figure 15: U.S. Animal Model Market Analysis 2017-2021 and Forecast 2022- 2032, By Therapeutic Area
Figure 16: U.S. Animal Model Market Analysis 2017-2021 and Forecast 2022- 2032, By Therapeutic Area
Figure 17: U.S. Animal Model Market Attractiveness Analysis, By Therapeutics
Figure 19: U.S. Animal Model Market Y-o-Y Growth (%) By End User, 2022-2032
Figure 20: U.S. Animal Model Attractiveness Analysis, By End User
Table 1: U.S. Animal Model Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Species
Table 2: U.S. Animal Model Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Application
Table 3: U.S. Animal Model Market Analysis 2017-2021 and Forecast 2022- 2032, By Therapeutic Area
Table 4: U.S. Animal Model Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By End User